Roshann L. Hooshmand, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 55 Route 130, Forestdale, MA 02644 Phone: 508-477-5306 Fax: 508-477-0297 |
Marie Kayton, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 55 Route 130, Forestdale, MA 02644 Phone: 508-477-5306 Fax: 508-477-0297 |
Dr. Ann M Deweer Aviles, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 55 Route 130, Forestdale, MA 02644 Phone: 508-477-5306 |
Alexander C. Heard, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 55 Route 130, Forestdale, MA 02644 Phone: 508-477-5306 Fax: 508-477-0297 |
Ciera Joyce Maffei, CPNP Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 55 Route 130, Forestdale, MA 02644 Phone: 508-477-5306 Fax: 508-477-0297 |
Andrew M Bonwit, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 55 Route 130, Forestdale, MA 02644 Phone: 508-477-5306 Fax: 508-477-0297 |
News Archive
Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin.
EyeStat (blinktbi, Charleston, SC), a portable, lightweight device for measuring the natural blink reflex, received clearance by the U.S. Food and Drug Administration in December 2019.
A new paper to be published in The Journal of Shoulder and Elbow Surgery evaluates the effect that topical benzoyl peroxide (BPO), with chlorhexidine skin preparation, has on the presence of Propionibacterium acnes cultured at the time of shoulder surgery. The authors hypothesized that adding topical BPO, the active ingredient in Clearasil, to the pre-operative skin preparation would reduce the number of positive P. acnes cultures identified during surgery.
The number of children with a certain blood disorder undergoing an ultrasound to help prevent stroke is up significantly in the past 10 years since the publication of a major study showing its benefits.
Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that its majority-owned subsidiary, Perseid Therapeutics LLC, achieved a second preclinical milestone under its collaboration with Astellas Pharma Inc. to co-develop and commercialize next-generation CTLA4-Ig therapeutics.
› Verified 8 days ago